SN-38

Generic Name: SN-38

Brand Names: Trodelvy

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₀N_₂O_₅

CAS Number: 86639-52-3

Unique Ingredient Identifier: 0H43101T0J

Background: 7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan Irinotecan, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negat...

Indication: Investigated for use/treatment in colorectal cancer.

Associated Conditions: Hormone Receptor Positive Metastatic Breast Cancer, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Triple Negative Breast Cancers, Unresectable Triple-Negative Breast Carcinoma, Metastatic HR Positive, HER2/Neu Negative Breast Cancer, Unresectable Locally Advanced Triple-negative Breast Cancer, Unresectable, locally advanced HR Positive, HER2/Neu Negative Breast Cancer, Unresectable, locally advanced Hormone Receptor Positive Breast Carcinoma

Associated Therapies: -

Clinical Trials

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Phase 1

Recruiting

Conditions: Metastatic Breast Cancer
Advanced Breast Cancer

Interventions: Drug: Sacituzumab Govitecan
Drug: Trastuzumab Deruxtecan
Drug: Hydroxychloroquine

First Posted Date: 2024-03-25

Last Posted Date: 2024-03-25

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 120

Registration Number: NCT06328387

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Phase 2

Not yet recruiting

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm

Interventions: Procedure: Biopsy
Other: Electronic Health Record Review
Procedure: Biospecimen Collection
Other: Immunohistochemistry Staining Method
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Echocardiography
Drug: Enfortumab Vedotin
Biological: Sacituzumab Govitecan
Procedure: Multigated Acquisition Scan
Biological: Trastuzumab Deruxtecan

First Posted Date: 2024-03-15

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT06311214

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Phase 2

Recruiting

Conditions: Hormone-receptor-positive Breast Cancer
Human Epidermal Growth Factor 2 Low Breast Cancer
Breast Cancer
Metastatic Breast Cancer
Advanced Breast Cancer

Interventions: Drug: Sacituzumab govitecan

First Posted Date: 2024-02-16

Last Posted Date: 2024-11-22

Lead Sponsor: Reshma L. Mahtani, D.O.

Target Recruit Count: 75

Registration Number: NCT06263543

Locations: 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

Phase 2

Recruiting

Conditions: Thymic Carcinoma
Thymoma

Interventions: Drug: Sacituzumab govitecan-hziy

First Posted Date: 2024-02-08

Last Posted Date: 2024-11-27

Lead Sponsor: Georgetown University

Target Recruit Count: 18

Registration Number: NCT06248515

Locations: 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Phase 1

Recruiting

Conditions: Breast Cancer
Triple Negative Breast Cancer

Interventions: Radiation: Stereotactic Radiation
Drug: Zimberelimab
Drug: Sacituzumab govitecan

First Posted Date: 2024-02-02

Last Posted Date: 2024-11-14

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 31

Registration Number: NCT06238921

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

Phase 2

Recruiting

Conditions: Breast Cancer Stage IV

Interventions: Drug: Sacituzumab Govitecan

First Posted Date: 2024-02-01

Last Posted Date: 2024-07-19

Lead Sponsor: SOLTI Breast Cancer Research Group

Target Recruit Count: 50

Registration Number: NCT06236269

Locations: 🇪🇸
ICO Badalona, Badalona, Barcelona, Spain
🇪🇸
Hospital Universitari Vall d'Hebrón, Barcelona, Spain
🇪🇸
HU Clínico San Cecilio, Granada, Spain

and more 7 locations

Sacituzumab govitEcan in THYroid Cancers

Phase 2

Recruiting

Conditions: Differentiated Thyroid Cancer
Anaplastic Thyroid Cancer

Interventions: Drug: Sacituzumab govitecan

First Posted Date: 2024-01-31

Last Posted Date: 2024-11-01

Lead Sponsor: Grupo Espanol de Tumores Neuroendocrinos

Target Recruit Count: 42

Registration Number: NCT06235216

Locations: 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸
Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain
🇪🇸
Institut Catala d´Oncologia (ICO) -Hospitalet, Hospitalet de Llobregat (Barcelona), Spain

and more 8 locations

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: GS-0201
Drug: Sacituzumab Govitecan

First Posted Date: 2023-12-12

Last Posted Date: 2024-12-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 254

Registration Number: NCT06167317

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
🇮🇱
Chaim Sheba Medical Center, Tel Hashomer, Israel

and more 4 locations

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Phase 2

Recruiting

Conditions: Small Cell Carcinoma of the Bladder
Squamous Cell Carcinoma of the Urinary Tract
Small Cell Carcinoma of the Urinary Tract
Renal Medullary Carcinoma
Primary Adenocarcinoma of the Bladder
Primary Adenocarcinoma of the Urinary Tract
Squamous Cell Carcinoma of the Bladder
Squamous Cell Carcinoma of the Penis

Interventions: Drug: Sacituzumab govitecan
Drug: Atezolizumab

First Posted Date: 2023-12-08

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT06161532

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Phase 2

Not yet recruiting

Conditions: Urothelial Bladder Carcinoma

Interventions: Drug: Sacituzumab govitecan
Drug: Zimberelimab
Drug: Domvanalimab

First Posted Date: 2023-11-15

Last Posted Date: 2024-08-29

Lead Sponsor: Fundación para el Progreso de la Oncología en Cantabria

Target Recruit Count: 70

Registration Number: NCT06133517

Locations: 🇪🇸
ICO Badalona, Badalona, Barcelona, Spain
🇪🇸
Hospital Duran i Reynals (ICO L´Hospitalet), L'Hospitalet De Llobregat, Barcelona, Spain
🇪🇸
Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy